简体中文 (Chinese Simplified)
正體中文 (Chinese Traditional)
日本語 (Japanese)
Español (Argentina)
Portuguese (Brazil)
پارسی (Persian)
Български (Bulgarian)
Ελληνικά (Greek)
Tiếng Việt (Vietnamese)
한국어 (Korean)
Norwegian (bokmål)

Annals of Oncology - Advance Access

Annals of Oncology - RSS feed of articles

Latest articles

EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†

AbstractBackgroundAlthough guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial.ObjectiveTo bring together a large multidisciplinary group of experts to develop consensus statements on controversial topics in bladder cancer management.DesignA...

Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and 1st-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial

AbstractIntroductionFIRE-3 compared 1st-line therapy with FOLFIRI plus either cetuximab or bevacizumab in 592 KRAS exon 2 wild-type mCRC patients. The Consensus Molecular Subgroups (CMS) are grouping CRC samples according to their gene-signature in four different subtypes. Relevance of CMS for the treatment of mCRC has yet to be defined.MethodsIn this...

Predictive modeling in colorectal cancer: time to move beyond Consensus Molecular Subtypes

When is off-label off-road?

Reasons to be testing: the dawn of complex molecular profiling in routine oncology practice

SummarySelf-learning healthcare systems are becoming a reality. As boundaries between research and healthcare delivery become increasingly blurred, there is an emerging opportunity to accelerate learning through the cyclical integration and analysis of patient phenotype, treatment and clinical outcome. Opportunities already exist to save money through...

Systemic treatment of biliary tract cancer: now we have evidence

Lymphocyte infiltration predicts survival in chemotherapy-naïve, triple negative breast cancer, and identifies patients with intrinsically good prognosis: Have we been bringing owls to Athens?

Management of toxicity to isoform α-specific PI3K inhibitors

AbstractAlterations in the PI3K/AKT pathway are frequently found in cancer and are especially common in breast cancer, where it is estimated that 70% of tumors have some type of genetic alteration that could lead to pathway hyperactivation. A variety of PI3K pathway inhibitors have been developed in an attempt to target this pathway and improve cancer...

Cancer-Related Cognitive Impairment: An update on state of the art, detection, and management strategies in cancer survivors

AbstractBackgroundAdvances in diagnostic and therapeutic strategies in oncology have significantly increased the chance of survival of cancer patients, even those with metastatic disease. However, cancer-related cognitive impairment (CRCI) is frequently reported in patients treated for non-central nervous system cancers, particularly during and after...

Patient reported outcomes and genomic signatures: tools to tailor adjuvant endocrine treatment?

Discover, share and read the best on the web

Subscribe to RSS Feeds, Blogs, Podcasts, Twitter searches, Facebook pages, even Email Newsletters! Get unfiltered news feeds or filter them to your liking.

Get Inoreader
Inoreader - Subscribe to RSS Feeds, Blogs, Podcasts, Twitter searches, Facebook pages, even Email Newsletters!